期刊
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
卷 6, 期 -, 页码 1-7出版社
CELL PRESS
DOI: 10.1016/j.omtm.2017.03.008
关键词
-
资金
- Ministerio de Economia y Competitividad
- Plan Nacional I+D+I from MINECO [SAF2011-24698, SAF2014-54866-R]
- European Regional Development Fund (ERDF)
- Generalitat de Catalunya [2014SGR-1669]
- ICREA
- European Commission MYOCURE [PHC-14-2015-667751]
- Ministerio de Economia y Competitividad, Spain [BES-2015-075799]
Diabetes is a complex metabolic disease that exposes patients to the deleterious effects of hyperglycemia on various organs. Achievement of normoglycemia with exogenous insulin treatment requires the use of high doses of hormone, which increases the risk of life-threatening hypoglycemic episodes. We developed a gene therapy approach to control diabetic hyperglycemia based on co-expression of the insulin and glucokinase genes in skeletal muscle. Previous studies proved the feasibility of gene delivery to large diabetic animals with adeno-associated viral (AAV) vectors. Here, we report the long-term (similar to 8 years) follow-up after a single administration of therapeutic vectors to diabetic dogs. Successful, multi-year control of glycemia was achieved without the need of supplementation with exogenous insulin. Metabolic correction was demonstrated through normalization of serum levels of fructosamine, triglycerides, and cholesterol and remarkable improvement in the response to an oral glucose challenge. The persistence of vector genomes and therapeutic transgene expression years after vector delivery was documented in multiple samples from treated muscles, which showed normal morphology. Thus, this study demonstrates the long-term efficacy and safety of insulin and glucokinase gene transfer in large animals and especially the ability of the system to respond to the changes in metabolic needs as animals grow older.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据